Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recently, non-invasive brain stimulation modalities such as transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation have become treatment options. Among these methods, rTMS is a non-invasive brain stimulation technique that can affect descending corticospinal pathways, thereby modulating cortical excitability in the motor area where it is applied. This study will examine the effect of rTMS application on spasticity and balance in patients with multiple sclerosis. In addition, the indirect effects of the applications on gait pattern, joint range of motion, and pain will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| rTMS M1 | Active Comparator | rTMS application on M1 cortex |
|
| sham rTMS | Placebo Comparator | sham rTMS application on M1 cortex |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| rTMS | Device | Low frequency rTMS application on M1 cortex |
| |
| sham rTMS |
| Measure | Description | Time Frame |
|---|---|---|
| Modified Ashworth Scale | It is designed to determine the level of spasticity. Accordingly, 0: no increase in muscle tone, 1: minimal resistance at the end of joint range of motion or a slight increase in muscle tone manifested as catching and releasing, 1+: increase in muscle tone characterized by minimal resistance developing over a smaller portion of the last half of joint range of motion, 2: increase in muscle tone that is noticeable but does not allow joint movement over a large portion of joint range of motion, allows joint movement, 3: Increased muscle tone that impedes passive movement, 4: Joint is rigid in flexion or extension. Spasticity in the patients' lower extremity muscles will be assessed. | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| Penn Spasm Frequency Scale | It is a measure that determines the frequency of spasms. Spasm frequency is rated on a 5-point scale: Spasm Frequency Spasm Severity 0: No spasms, 1: Mild spasms induced by stimulation, 2: Complete spasms occurring less than once per hour, 3: Spasms occurring more than once per hour, 4: Spasms occurring more than ten times per hour. | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| Modified Tardieu Scale | Muscle tone is assessed at 5 degrees at predetermined speeds. The first angle at which increased resistance is detected in the joint is recorded. It is compared to the angle when the range of motion is complete. 0: No resistance during passive movement, 1: Mild resistance during passive movement but no catching sensation at any specific angle, 2: Passive movement is interrupted at a specific angle with a catching sensation, followed by relaxation, 3: Resistance continues, movement is interrupted at a specific angle with a catching sensation, followed by relaxation, 3: When pressure is maintained, fatigue occurs at a specific angle for less than 10 seconds, causing clonus lasting more than 10 seconds at a specific angle when pressure is maintained, Unassessable: Inconsistent measurements or the absence of relaxation after a catching sensation at different angles is considered. modified Tardieu scores will be recorded for the hamstring and gastrocnemius |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analogue Scale (VAS) | This is a scale used to assess patients' pain levels. It is rated on a scale of 0 to 10 points. A score of 0 indicates no pain, while a score of 10 reflects the most severe pain ever experienced. | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Melike Çil, specialist | Contact | +90 0312 797 00 00 | +903122911000 | melike9671@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Özgür Zeliha Karaahmet, professor | Ankara Etlik City Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ankara Etlik City Hospital | Recruiting | Ankara | Yenimahalle | 06010 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36131925 | Background | Zhou X, Li K, Chen S, Zhou W, Li J, Huang Q, Xu T, Gao Z, Wang D, Zhao S, Dong H. Clinical application of transcranial magnetic stimulation in multiple sclerosis. Front Immunol. 2022 Sep 5;13:902658. doi: 10.3389/fimmu.2022.902658. eCollection 2022. | |
| 27481208 | Background | Boutiere C, Rey C, Zaaraoui W, Le Troter A, Rico A, Crespy L, Achard S, Reuter F, Pariollaud F, Wirsich J, Asquinazi P, Confort-Gouny S, Soulier E, Guye M, Pelletier J, Ranjeva JP, Audoin B. Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices. Mult Scler. 2017 May;23(6):855-863. doi: 10.1177/1352458516661640. Epub 2016 Aug 1. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D009128 | Muscle Spasticity |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Device |
Low frequency sham rTMS |
|
| patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| BERG Balance Scale | It is a scale consisting of 14 guidelines, with the patient's performance observed for each guideline and scored on a scale of 0-4. A score of 0 is given when the patient is unable to perform the activity at all, while a score of 4 is given when the patient completes the activity independently. The maximum score is 56, with 0-20 points indicating balance impairment, 21-40 points indicating acceptable balance, and 41-56 points indicating good balance. | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| Goal Attainment Scale | It allows for the assessment and measurement of individualized, predefined goals on a 5-point scale ranging from -2 to +2. In this study, the extent to which spasticity in the muscle group with the highest spasticity at baseline and at the 1-month follow-up changed from the MAS to the GAS was evaluated.
| patients will be checked on first day of hospitalization and after treatment 1 month |
| Expanded Disability Status Scale (EDSS) |
Multiple Sclerosis (MS) patients It is a measure used to assess the level of physical disability caused by the disease. Based on neurological examination findings, it allows for objective monitoring of the course of the disease and functional status. EDSS Assessment Criteria:. 0.0 - 3.5: Minimal or mild disability. The patient's ability to walk is not affected, but there may be mild problems in some functional systems (e.g., vision, sensation, coordination). . 4.0 - 5.5: Moderate disability. The patient feels a significant limitation in their walking capacity, but can usually walk short distances without assistance.. 6.0 - 7.5: More severe walking difficulties. The patient requires assistive devices (e.g., cane, walker) or can only walk short distances without assistance.. 8.0 - 9.5: Bed or wheelchair dependency. The patient is mostly unable to meet their own needs independently.. 10.0: Death, due to causes directly related to MS. |
| patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| Functional Independence Measure (FIM) | It is a measure used to determine individuals' independence levels by assessing their physical, psychosocial, and social skills. It is widely used to monitor the independence level of patients, especially during the rehabilitation process. It contains a total of 18 items: 13 items assess motor skills, and 5 items assess social and cognitive skills. Each item is scored from 1 to 7. The total score range varies from 18 (completely dependent) to 126 (completely independent). | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| Multiple Sclerosis Quality of Life-54 (MSQoL-54) | It consists of 54 questions, and the scale is evaluated based on the answers to questions related to changes in health status, physical functions, general health perception, energy/fatigue, physical role limitations, pain, sexual functions, sexual life satisfaction, social functions, health-related concerns, overall quality of life, emotional well-being, emotional role limitations, and cognitive functions. The results are then used to calculate the physical health status average, cognitive health status average, and MSQOL-54 total score. | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| Six Minute Walk Test | It is a practical test used to determine an individual's functional capacity. The test involves walking on a flat surface for 6 minutes according to a standardized protocol. The distance walked within 6 minutes is evaluated using this method. | patients will be checked on first day of hospitalization, after treatment at 2 weeks and after treatment 1 month |
| 31591833 | Background | San AU, Yilmaz B, Kesikburun S. The Effect of Repetitive Transcranial Magnetic Stimulation on Spasticity in Patients with Multiple Sclerosis. J Clin Neurol. 2019 Oct;15(4):461-467. doi: 10.3988/jcn.2019.15.4.461. |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009122 | Muscle Hypertonia |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |